Can angiogenesis inhibitor therapy cause changes in imaging features of hepatic hemangioma- Initial study [PDF]
Frontiers in Oncology, 2023 BackgroundTo observe whether anti-angiogenesis therapy can induce changes in size and enhancement characteristics of hepatic hemangioma.Method133 patients with hepatic hemangioma lesions were analyzed and classified into a Bevacizumab group (n=65) and ...
Tang Liu +3 more
doaj +2 more sources
First‐line immunotherapy or angiogenesis inhibitor combined with chemotherapy for advanced non‐small cell lung cancer with EGFR exon 20 insertions: Real‐world evidence from China [PDF]
Cancer Medicine, 2023 Background Currently, survival benefit of immunotherapy in advanced non‐small cell lung cancer (NSCLC) with EGFR exon 20 insertions (ex20ins) is controversial, though it generally indicates poor response and activity.
Guangjian Yang +10 more
doaj +2 more sources
Case report: Pathological complete response to perioperative treatment of radiotherapy combined with angiogenesis inhibitor in a patient with pleomorphic liposarcoma [PDF]
Frontiers in Oncology, 2023 BackgroundLiposarcomas (LPS) are mesenchymal malignancies with four principal subtypes presenting distinct molecular and clinical features. Pleomorphic liposarcoma (PLPS) is one of the rarest and most aggressive subtypes of LPS.
Chenlu Zhang +11 more
doaj +2 more sources
Impact of angiogenesis inhibitor eligibility on the prognosis of patients with non‐small cell lung cancer harboring EGFR mutation [PDF]
Cancer Medicine, 2021 Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) are currently the primary treatment option for patients with EGFR‐mutant non‐small cell lung cancer (NSCLC).
Hiroaki Kodama +15 more
doaj +2 more sources
Editorial: Angiogenesis and Angiogenesis Inhibitors in Oral Cancer [PDF]
Frontiers in Oral Health, 2021 Non peer ...
Abdelhakim Salem +5 more
doaj +4 more sources
Major Adverse Cardiovascular Events in Angiogenesis Inhibitor‐Based Cancer Therapy: A Systematic Review and Meta‐Analysis [PDF]
Journal of the American Heart Association: Cardiovascular and Cerebrovascular DiseaseBackground Angiogenesis inhibitors (AIs) are effective in cancer therapy due to their ability to suppress tumor vasculature. However, these agents are associated with significant cardiovascular toxicities, including hypertension, thrombosis, and heart ...
Yuxuan Tao +5 more
doaj +2 more sources
Global Dormancy of Metastases Due to Systemic Inhibition of Angiogenesis [PDF]
, 2014 Autopsy studies of adults dying of non-cancer causes have shown that virtually all of us possess occult, cancerous lesions. This suggests that, for most individuals, cancer will become dormant and not progress, while only in some will it become ...
Benzekry, Sébastien +2 more
core +21 more sources
On-Target Side Effects of Targeted Therapeutics of Cancer
Pathology and Oncology Research, 2022 The concept of precision medicine is based on the identification of hallmarks of cancer to exploit them as drug targets. The basic idea was that in this way the therapeutic modalities will be more effective and the side effects will be less.
József Tímár, Andrea Uhlyarik
doaj +1 more source
Body Composition to Define Prognosis of Cancers Treated by Anti-Angiogenic Drugs
Diagnostics, 2023 Background: Body composition could help to better define the prognosis of cancers treated with anti-angiogenics. The aim of this study is to evaluate the prognostic value of 3D and 2D anthropometric parameters in patients given anti-angiogenic treatments.
Pierre Decazes +10 more
doaj +1 more source
Российский офтальмологический журнал, 2023 Purpose: data analysis of Russia’s first register of neovascular age-related macular degeneration (nAMD) — a web-based system for clinical monitoring of nAMD patients designed to collect and accumulate the data on such patients, their demographic, social
V. V. Neroev +4 more
doaj +1 more source